London-based Spex Capital, an early-stage investor in healthtech companies, announced on Monday the launch of Spex Venture HealthTech Fund with a target size of €100M.
With the new fund, the companyl will invest globally in early-stage healthtech ventures, from seed to Series A, up to €5M.
Spex Capital says the fund is a designated Article 9 impact fund under the EU’s Sustainable Finance Disclosure Regulation (SFDR).
Claudio D’Angelo, Founder and CEO of Spex Capital, says, “Even before Covid-19, the drive for countries to make better use of digital technology in healthcare had already begun. With this fund, our partnership with MedCity, and a broad network of high calibre Senior Advisors, we will have unparalleled access to invest in the best startups within this space.”
Spex Capital: Helping early-stage ventures
Founded by serial healthtech entrepreneur Claudio D’Angelo in 2021, Spex Capital is a digital health and med-tech investment management firm focusing on early-stage ventures to deliver breakthroughs in healthcare systems globally.
To date, the company has closed ten investments in this space.
Currently, Spex Capital has a two-year ongoing partnership with MedCity, which represents London’s life sciences cluster, collaborating with the city’s leading academic centres to connect private industry with partners in the NHS, the charity sector, and research institutes.
Additionally, Spex Capital has announced the appointment of Brent Stackhouse, Managing Director of Mount Sinai Ventures, to the team.
Spex Capital says Stackhouse has a wealth of experience from investing in the US healthcare system and will offer a springboard for the overseas expansion of the companies the fund will invest in.
Stackhouse says, “I’m excited to take part in the launch of the Spex Venture HealthTech Fund at a time of radical change for the healthtech sector. History has shown us time and time again that economic downturns provide an impetus for innovation and that some of the strongest vintages have come from recession years.”
“We now have an opportunity to acquire high-quality assets at discounted valuations. We look forward to shaping the global healthcare ecosystem by helping innovators in developing ground-breaking technologies and solutions to overcome healthcare challenges worldwide.”